Supervision standards shift. Coding structures get rebuilt. Arrangements that were defensible three years ago draw scrutiny now. Compliance in oncology is not a fixed target, and treating it as one is how growth plans get unwound after the fact.
We build governance that lets the program move.
Compliance Is a Growth Function
Most compliance work in oncology is reactive. It begins after an audit letter, after a self-disclosure, after an arrangement has already been papered. By that point the options are narrow and expensive.
Programs that grow without incident treat compliance as a governance layer underneath every capital decision, every physician arrangement, every technology deployment, and every new modality. Independence is not a philosophical posture here. It is a fiduciary necessity, because most of the advisors evaluating those decisions have a financial interest in the outcome.
What We Do
Regulatory Alignment
CMS, OIG, and DOJ frameworks applied to supervision structure, documentation standards, and coding practice.
Audit Readiness and Defense
Preparation before the letter arrives and response after it does.
Arrangement and Contract Review
Physician alignment, joint ventures, MSOs, and vendor agreements assessed for regulatory exposure before they are signed.
Governance for New Technology
AI deployment, scope of practice, and liability, evaluated before implementation rather than after.
We Have Helped Write the Rules
Our legal and clinical expertise sit in the same room. Jordan Johnson has served as an expert witness for the Department of Justice and the Office of Inspector General. Bridge’s analysis contributed to the expansion of Direct Virtual Supervision in the 2024 Medicare Physician Fee Schedule Final Rule.
We do not just interpret the regulations. We have helped change them.
A compliance readiness review assesses your regulatory exposure across supervision, documentation, and arrangements, and tells you what to fix first.
